Retrospective Analysis of Viral Load and SIV Antibody Responses in Rhesus Macaques Infected with Pathogenic SIV: Predictive Value for Disease Progression
- 10 December 1999
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 15 (18), 1691-1701
- https://doi.org/10.1089/088922299309739
Abstract
The prognostic significance of SIV plasma viral load in macaques has not been well established, primarily owing to the small numbers of animals in experimental groups. In addition, many investigators have noted that animals that fail to develop an anti-SIV humoral response develop disease rapidly. To establish the prognostic significance of viral load and seroconversion, we retrospectively analyzed the plasma viral load and serology data from 74 rhesus macaques infected with SIVmac. Viral load was analyzed at three time points: in the peak (days 7-21), acute (days 30-55), and chronic (days 80-100) periods postinfection. High viral load in the peak and acute phases was associated with more rapid development of disease (p = 0.0086, p = 0.0004, respectively). We defined clinical outcome as rapid (< 1 year) or slow (>= 1 year) progression. When peak and acute viral loads were analyzed together, acute viral load was more strongly associated with rapid progression (p = 0.03). Slow progression was strongly associated with chronic viral loads below the median of 3.47 X 105 RNA copies/ml. Despite having preexisting anti-SIV antibodies, 7 of 23 vaccinated animals were rapid progressors. All unvaccinated animals that mounted a humoral response to SIV were slow progressors. Animals that received a formalin-fixed, microencapsulated SIV vaccine prior to infection had lower peak viral loads than unvaccinated animals (p = 0.0005), but developed disease at the same rate. Overall, in naive animals, viral load is an important prognostic indicator of the disease progression rate. We found that viral load measured during the chronic phase (days 80-100) of infection was most closely associated with disease progression. We also found that a formalin-fixed, microencapuslated SIV vaccine reduced viral load without affecting clinical outcome. This latter finding may have implications for the evaluation of HIV-1 human vaccine trials.Keywords
This publication has 43 references indexed in Scilit:
- A Genetic and Viral Load Analysis of the Simian Immunodeficiency Virus during the Acute Phase in Macaques Inoculated by the Vaginal RouteAIDS Research and Human Retroviruses, 1998
- Prognostic Value of Serum HIV-RNA Levels at Virologic Steady State After Seroconversion: Relation to CD4 Cell Count and Clinical Course of Primary InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 1997
- Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virusJournal of General Virology, 1996
- Macaque models for AIDS vaccine developmentCurrent Opinion in Immunology, 1996
- Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in PlasmaScience, 1996
- Longitudinal serum HIV RNA quantification: correlation to viral phenotype at seroconversion and clinical outcomeAIDS, 1996
- Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cellsThe Lancet, 1995
- Protective Effects of a Live Attenuated SIV Vaccine with a Deletion in the nef GeneScience, 1992
- The biology and immunopathology of simian immunodeficiency virus infectionCurrent Opinion in Immunology, 1990
- Induction of AIDS-Like Disease in Macaque Monkeys with T-Cell Tropic Retrovirus STLV-IIIScience, 1985